Novartis reports positive data for neuromuscular disorder drug
- Posted on June 11, 2026
- By Bing News
- 0 Views
- 1 min read
Novartis reports positive data for neuromuscular disorder drug
Novartis NVS announced positive data from the biomarker cohort of the FORTITUDE phase I/II study. The FORTITUDE phase I/II study is a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of delpacibart braxlosiran (del-brax) in patients with facioscapulohumeral muscular dystrophy (FSHD). Del-brax is an investigational antibody oligonucleotide conjugate...
